Company Innate Immunotherapeutics Ltd Australian S.E.
Equities
AU000000IIL6
Biotechnology & Medical Research
Business Summary
Sales per Business
AUD in Million | 2023 | Weight | 2024 | Weight | Delta |
---|---|---|---|---|---|
Focal Adhesion Kinase
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -63.46% |
Sales per region
AUD in Million | 2023 | Weight | 2024 | Weight | Delta |
---|---|---|---|---|---|
Australia
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -63.46% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 00-05-30 | |
Tim Luscombe
DFI | Director of Finance/CFO | - | 23-09-24 |
Rhiannon Jones
COO | Chief Operating Officer | - | 21-01-31 |
Charlotte Mulder
PRN | Corporate Officer/Principal | - | - |
Mark Devlin
PRN | Corporate Officer/Principal | - | - |
Andrew Cooke
SEC | Corporate Secretary | 62 | 13-10-10 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Cooke
SEC | Corporate Secretary | 62 | 13-10-10 |
Robert Peach
BRD | Director/Board Member | 68 | 15-09-01 |
Warwick Tong
CHM | Chairman | - | 18-05-03 |
Founder | - | 00-05-30 | |
Jane Bell
BRD | Director/Board Member | - | 21-04-11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 271,608,953 | 222,004,662 ( 81.74 %) | 0 | 81.74 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+19.33% | 125B | |
+14.31% | 108B | |
-4.08% | 24.57B | |
+3.23% | 22.82B | |
-10.44% | 18.19B | |
-41.74% | 16.54B | |
-12.36% | 16.5B | |
+2.66% | 13.39B | |
+27.47% | 11.1B |